Progress in Assays of HMGB1 Levels in Human Plasma-The Potential Prognostic Value in COVID-19

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Science. Official publication website can be found on muni.cz.
Authors

ŠTROS Michal VOLFOVÁ POLANSKÁ Eva HLAVÁČOVÁ Tereza SKLÁDAL Petr

Year of publication 2022
Type Article in Periodical
Magazine / Source Biomolecules
MU Faculty or unit

Faculty of Science

Citation
Web https://www.mdpi.com/2218-273X/12/4/544
Doi http://dx.doi.org/10.3390/biom12040544
Keywords HMGB1; plasma/serum; ELISA; EMSA; immunosensor; COVID-19
Description Extracellular HMGB1 protein is known to induce inflammatory responses leading to an inflammatory storm. The outbreak of the Severe Acute Respiratory Syndrome COVID-19 due to the SARS-CoV-2 virus has resulted in a huge health concern worldwide. Recent data revealed that plasma/serum HMGB1 levels of patients suffering from inflammation-mediated disorders-such as COVID-19, cancer, and autoimmune disorders-correlate positively with disease severity and vice versa. A late release of HMGB1 in sepsis suggests the existence of a wide therapeutic window for treating sepsis. Rapid and accurate methods for the detection of HMGB1 levels in plasma/serum are, therefore, of great importance for monitoring the occurrence, treatment success, and survival prediction of patients with inflammation-mediated diseases. In this review, we briefly explain the role of HMGB1 in the cell, and particularly the involvement of extracellular HMGB1 (released from the cells) in inflammation-mediated diseases, with an emphasis on COVID-19. The current assays to measure HMGB1 levels in human plasma-Western blotting, ELISA, EMSA, and a new approach based on electrochemical immunosensors, including some of our preliminary results-are presented and thoroughly discussed.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.